NCT00134719 - Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines | Biotech Hunter

Enrollment

1,104

Participants

Timeline

Start Date

April 11, 2005

Primary Completion Date

July 24, 2006

Study Completion Date

February 21, 2007

Conditions

Neisseria MeningitidisHaemophilus Influenzae Type b

Interventions

BIOLOGICAL

MenHibrix (Hib-MenCY-TT)

One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)

BIOLOGICAL

Infanrix® Penta

One intramuscular dose at 2, 4 and 6 months of age

BIOLOGICAL

Prevenar®

One intramuscular dose at 2, 4 and 6 months of age

BIOLOGICAL

ActHIB®

One intramuscular dose at 2, 4 and 6 months of age

BIOLOGICAL

Meningitec®

One intramuscular dose at 2, 4 and 6 months of age

BIOLOGICAL

M-M-R®II

One subcutaneous dose at 12-15 months of age

BIOLOGICAL

Varivax®

One subcutaneous dose at 12 to 15 months of age

BIOLOGICAL

PedvaxHIB®

One intramuscular dose at 12 to 15 months of age

Trial Locations (3)

GSK Investigational Site, Carlton

GSK Investigational Site, North Adelaide

GSK Investigational Site, Perth